These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37609641)

  • 1. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease presenting with bilateral orbital involvement.
    Wang X; Cao J; Du W; Ma W; Meng B; Cao S
    Clin Case Rep; 2023 Aug; 11(8):e7780. PubMed ID: 37609641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Erdheim-Chester disease presenting with bilateral orbital involvement: Report of three cases].
    Kiratli H; Koç I; Söylemezoğlu F
    J Fr Ophtalmol; 2020 Nov; 43(9):851-857. PubMed ID: 32829941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
    Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the
    Oneal PA; Kwitkowski V; Luo L; Shen YL; Subramaniam S; Shord S; Goldberg KB; McKee AE; Kaminskas E; Farrell A; Pazdur R
    Oncologist; 2018 Dec; 23(12):1520-1524. PubMed ID: 30120160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erdheim-Chester Disease: a Rare but Important Cause of Recurrent Pericarditis.
    Chahine J; Alzubi J; Alnajjar H; Ramchand J; Chetrit M; Klein AL
    Curr Cardiol Rep; 2020 Jun; 22(8):75. PubMed ID: 32607694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erdheim-Chester disease and vemurafenib: a review of ophthalmic presentations and clinical outcomes.
    Park JK; Huang LC; Kossler AL
    Orbit; 2023 Jun; 42(3):233-244. PubMed ID: 35702885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erdheim-Chester Disease: Two cases from an ophthalmic perspective.
    Brodie J; Zhou S; Makkuni D; Beadsmoore C; Mukhtyar C; Saada J; Bowles KM; Beigi B; Burton BJL
    Am J Ophthalmol Case Rep; 2020 Dec; 20():100984. PubMed ID: 33204897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orbital and chorioretinal manifestations of Erdheim-Chester disease treated with vemurafenib.
    Huang LC; Topping KL; Gratzinger D; Brown RA; Martin BA; Silva RA; Kossler AL
    Am J Ophthalmol Case Rep; 2018 Sep; 11():158-163. PubMed ID: 30094395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective.
    Kanakis M; Petrou P; Lourida G; Georgalas I
    Surv Ophthalmol; 2022; 67(2):388-410. PubMed ID: 34081930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoalphalipoproteinemia and BRAF
    Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports.
    Qiao J; Ma R; Peng X; He W
    World J Surg Oncol; 2023 Jul; 21(1):233. PubMed ID: 37525276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].
    Liu T; He TH; Niu N; Li J; Zhou DB; Cao XX
    Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):752-756. PubMed ID: 34753230
    [No Abstract]   [Full Text] [Related]  

  • 14. Erdheim-Chester Disease With Eyelid and Orbital Involvement: A Review of Treatment Modalities at One Institution From 2014 to 2022.
    Sharma M; Stevens SM; Maeng MM; Nagornaya N; Bhatia RG; Wester ST
    Ophthalmic Plast Reconstr Surg; 2024 Sep-Oct 01; 40(5):497-503. PubMed ID: 38427815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
    Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B
    Front Immunol; 2022; 13():918613. PubMed ID: 35874752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy.
    Mazor RD; Weissman R; Luckman J; Domachevsky L; Diamond EL; Abdel-Wahab O; Shapira S; Hershkovitz-Rokah O; Groshar D; Shpilberg O
    Neurooncol Adv; 2020; 2(1):vdaa024. PubMed ID: 32642685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.
    Goyal G; Heaney ML; Collin M; Cohen-Aubart F; Vaglio A; Durham BH; Hershkovitz-Rokah O; Girschikofsky M; Jacobsen ED; Toyama K; Goodman AM; Hendrie P; Cao XX; Estrada-Veras JI; Shpilberg O; Abdo A; Kurokawa M; Dagna L; McClain KL; Mazor RD; Picarsic J; Janku F; Go RS; Haroche J; Diamond EL
    Blood; 2020 May; 135(22):1929-1945. PubMed ID: 32187362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF-Mutated Erdheim-Chester Disease: Profound Response to Vemurafenib Visualized With Serial Multimodality Imaging.
    Gray JCR; Kim J; Digianvittorio M; Feeley NK; Scheel PJ; Siegelman SS; Fishman EK; Rowe SP
    J Natl Compr Canc Netw; 2020 Jun; 18(6):650-655. PubMed ID: 32502983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erdheim-Chester disease.
    Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
    Rheum Dis Clin North Am; 2013 May; 39(2):299-311. PubMed ID: 23597965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.